⌘K
Loading ticker…
As of 2026-08-24, Myriad Genetics Inc (MYGN) has a 3-month relative strength percentile of 20 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 37. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.6%, relative volume 0.48×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
MYGN is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -34.9% / -41.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
MYGN is held by 28 ETFs as of May 2026. Top owner: FNDA at 0.02% weight, $2M notional. Top 3 carry $6M.
Held by 56 ETFs · $65M across latest filings · largest weight 0.35% (QQQS).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| FNDA | 0.02% | $2M | — |
| VTWO | 0.01% | $2M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | — |
| VHTVanguard Health Care ETF | 0.01% | $1M | — |
| ESML | 0.04% | $1M | — |
| FSCC | 0.30% | $841K | −0.15 pp |
| GSSC | 0.05% | $517K | −0.06 pp |
| ISMD | 0.15% | $480K | +0.01 pp |
| VFMF | 0.07% | $467K | — |
| VFVA | 0.04% | $345K | −0.03 pp |
Showing 10 of 28 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MYGN Jan avg: 7.87% median: 2.08% win: 50% σ: 20.91% n: 4 2022-04-12 → 2026-07-31 | MYGN Feb avg: -9.87% median: -9.68% win: 0% σ: 7.93% n: 4 2022-04-12 → 2026-07-31 | MYGN Mar avg: 1.23% median: -0.26% win: 50% σ: 16.56% n: 4 2022-04-12 → 2026-07-31 | MYGN Apr avg: -8.22% median: -8.35% win: 20% σ: 8.47% n: 5 2022-04-12 → 2026-07-31 | MYGN May avg: -9.22% median: -6.15% win: 40% σ: 22.63% n: 5 2022-04-12 → 2026-07-31 | MYGN Jun avg: 15.51% median: 7.47% win: 80% σ: 19.66% n: 5 2022-04-12 → 2026-07-31 | MYGN Jul avg: -4.33% median: -3.58% win: 40% σ: 36.83% n: 5 2022-04-12 → 2026-07-31 | MYGN Aug avg: 7.93% median: -7.01% win: 50% σ: 39.71% n: 4 2022-04-12 → 2026-07-31 (current) | MYGN Sep avg: -3.64% median: -6.73% win: 25% σ: 12.33% n: 4 2022-04-12 → 2026-07-31 | MYGN Oct avg: -0.70% median: 2.92% win: 50% σ: 14.15% n: 4 2022-04-12 → 2026-07-31 | MYGN Nov avg: -2.70% median: -3.71% win: 25% σ: 19.84% n: 4 2022-04-12 → 2026-07-31 | MYGN Dec avg: -15.81% median: -17.57% win: 25% σ: 11.96% n: 4 2022-04-12 → 2026-07-31 |